Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.

A user is taking 1 mg finasteride daily with nanoxidil and wants to know how to mix finasteride tablets into a 60 ml nanoxidil bottle for topical use. They are concerned about side effects and considering switching to topical finasteride.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

The conversation discusses the pros and cons of buying a mixed topical bottle of minoxidil and finasteride versus separate products for hair loss treatment. Concerns are raised about the finasteride dosage and the inclusion of tretinoin in one of the products.

Mixing RU58841 powder into minoxidil can result in undissolved particles. Shaking the bottle and breaking up the grains may help dissolve it better.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

The conversation is about making a RU58841 solution for hair loss treatment. OP plans to create a video tutorial on it.

The conversation is about a user assessing their hair loss as Norwood 1.5 and discussing their use of oral minoxidil and finasteride for 2.5 years, which improved their hair density. They are content with their current progress but hope to reach Norwood 1.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The post is about using different solutions for RU58841, a treatment for hair loss. The user is asking for opinions on the effectiveness of different vehicles and dosages.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

The user experienced noticeable hair growth after starting dermarolling with a 1mm device, using minoxidil, and nizoral shampoo. They plan to reduce dermarolling frequency to three times a week and are considering additional treatments like finasteride or a hair transplant for increased hair density.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.

A user recently started using nanoxidil 5% for hair loss, particularly on the hairline, and is seeking feedback or experiences from others. The conversation focuses on the effectiveness of nanoxidil.

Topical dutasteride may have limited absorption due to its higher molecular mass compared to finasteride, potentially affecting its efficacy in suppressing DHT locally. Microneedling might enhance dutasteride absorption, possibly offering stronger local DHT suppression with fewer systemic effects.

The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

OP mixed RU58841 with minoxidil and noticed undissolved particles. They are seeking advice on whether it matters or how to fully dissolve it.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

Mixing minoxidil and alfatradiol in one bottle may affect their effectiveness due to potential stability issues. It's recommended to apply them separately for full benefits.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.